Forward Pharma Closed Series A Fundraising Lead by CSPC and Sangel Capital
Forward Pharmaceuticals Co., Ltd. ("Forward Pharma") announced the successful completion of a RMB 80 million Series A round financing. This round was lead by CSPC & Sangel Capital. The fund raised will accelerate the pipeline development - including a third-generation oral SERD, and R&D capability expansion.
Headquartered in Nanshan, Shenzhen, Forward Pharma is driven by a seasoned R&D team with extensive experience from leading global pharmaceutical companies. The company focuses on addressing unmet clinical needs through independent innovation.
Leveraging a dual-platform approach that integrates traditional medicinal chemistry and antibody screening with advanced computational tools - including computer-aided drug design (CADD), structural characterization, and computational chemistry - Forward has established a distinctive early stage drug discovery innovation system. This enables highly efficient development of novel targeted therapies.
Forward Pharma's pipeline includes FWD1802, a third-generation oral selective estrogen receptor degrader (SERD) for breast cancer, as well as other candidates such as FWB1313 - an IL-13-specific monoclonal antibody for severe asthma and atopic dermatitis, and small molecule inhibitors targeting KRAS G12C/G12D mutations.
"We invest in companies with distinct capabilities, competitive products, and exceptional talent," said Liu Jinglong, Executive Partner of Sangel Capital. "Forward Pharma’s differentiated R&D strategy and innovation capacity align with our vision. We look forward to supporting their growth and clinical progress."
Han Fengjin, Managing Partner of CSPC/Sangel Capital, added: "Forward Pharma is dedicated to research and innovation that addresses unmet clinical needs in major disease areas. The company has established unique competitive advantages through its differentiated pipeline, strategic development approach, strong technical capabilities, and efficient execution. We are highly impressed by their progress and are committed to leveraging our resources and network to support Forward Pharma’s rapid growth. We look forward to the company emerging as a globally competitive pharmaceutical enterprise".
About CSPC Capital
CSPC Capital is a venture capital focused on innovative drugs and cutting-edge technology platforms. Backed by its pharmaceutical industry shareholder, CSPC (01093.HK), CSPC Capital excels in opportunity identification, valuation, and post-investment portfolio management. The firm is committed to creating win-win outcomes for both its limited partners and portfolio companies.
About Sangel Capital
Sangel Capital is one of the earliest biomedical-oriented equity investment institutions in China. It focuses on the pharmaceuticals, medical devices, and biotechnology sectors, and has a strong track record of incubating leading companies in well-defined niche markets. With offices in Shenzhen, Beijing, Suzhou, and the United States, Sangel leverages cross-border collaboration to assemble a team of industry experts, scientists, and seasoned investors in life sciences. The firm manages both USD and RMB denominated funds and has been recognized with awards from various institutions.